COVID-19 vaccine developer CanSinoBIO seeks to raise $743m in STAR IPO

COVID-19 vaccine developer CanSinoBIO seeks to raise $743m in STAR IPO

CanSino Biologics Inc (CanSinoBIO), a Chinese biopharmaceutical company that is developing a COVID-19 vaccine candidate, plans to raise a total of 5.2 billion yuan ($743 million) in an initial public offering (IPO) on Shanghai’s Nasdaq-style STAR Market, according to a company filing on Thursday. 

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter